Edwards SAPIEN XT Valve Meets Primary Endpoint In PARTNER II Trial

Stifel Raises Price Target on Edwards Lifesciences (EW) to $117; Reiterates Buy

Stifel reiterated a Buy rating on Edwards Lifesciences (NYSE: EW), and raised the price target to $117.00 (from $98.00), following data presentations at American College of Cardiology. Given the outstanding data, Stifel is increasing its 2016-2020 revenue and EPS projections. On EPS, they now project 2016 at $2.67, up $0.06 from prior estimates and 2017 moves to $3.36, up $0.36 or 12% vs prior projection.

Analyst Rick Wise... More

BTIG Upgrades Edwards Lifesciences (EW) to Buy

BTIG upgraded Edwards Lifesciences (NYSE: EW) from Neutral to Buy with a price target of $115. The upgrade follows strong SAPIEN 3... More

Edwards Lifesciences (EW) PT Raised to at Jefferies Following PARTNER II Sapien 3 Data

Jefferies analyst Raj Denhoy reiterated a Buy rating and boosted his price target on Edwards Lifesciences (NYSE: EW) to $105.00 (from $100.00) after the much anticipated PARTNER II Sapien 3 data did not disappoint.

Denho commented, "Showing superiority to surgery on the primary endpoint... More

Edwards Lifesciences (EW) Announces Strong SAPIEN 3 TAVR Data vs. Surgery

Edwards Lifesciences Corporation (NYSE: EW) announced that new data on patients at intermediate risk for open-heart surgery demonstrated that transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 valve was superior to surgery at one year on a composite primary endpoint of mortality, stroke and moderate or severe aortic regurgitation. In addition, the SAPIEN 3 valve demonstrated clinical superiority at one year on individual assessments of all-cause mortality and of stroke. The results of the study of 1,078 enrolled patients with severe, symptomatic aortic stenosis were presented as part of the late-breaking clinical trials at the American College... More